The invention relates to a composition comprising immunoglobulins specific to influenza virus, at the exclusion of immunoglobulins from a convalescent human, for use as a medicament for the passive immunisation of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus, or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 µg of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus.
